Foremerly dba as Triangle Therapeutics, Trethera is structured around development of nucleotide metabolism drugs designed to provide treatment of cancer and autoimmune diseases. The company's drugs are deoxycytidine kinase inhibitor that improves bioavailability and demonstrates anti-tumour activity in combination therapies, enabling patients to avail of drugs that improve treatment efficacy and overcome the limitations of single-agent therapies.
